Fig. 1

Study population and treatment cohorts. Anti-TNFα: anti-tumor necrosis factor alpha; CD: Crohn’s disease; UC: ulcerative colitis; VDZ: vedolizumab
Study population and treatment cohorts. Anti-TNFα: anti-tumor necrosis factor alpha; CD: Crohn’s disease; UC: ulcerative colitis; VDZ: vedolizumab